Integrated histology for quantitative digital pathology

Tissue-based biomarker investigation is a key step in pre-clinical / clinical drug development as it can serve either identification of novel therapeutic target, assessment of a surrogate marker of drug efficacy as well as prediction of a candidate compound benefit. To support novel therapies development at both pre-clinical and clinical level, we offer expert histology services relying on automated and standardized stainings capabilities spanning from monoplex to 7-plex marker panels and using either conventional chemistry or fluorescence revelation systems (immunohistochemistry/immunohistofluorescence).

Many types of samples – either tumor or normal tissue, originating from human or pre-clinical models – can be adressed using our platform. Multispectral images acquired on our Vectra Polaris are processed through image analysis to provide quantitative data including phenotyping, marker expression, as well as geographical distribution of cells within the samples. In addition, bespoke services can also be offered to specifically meet our clients’ needs.

Key advantages of tissue-based imaging

  • Exploration at multiple scales, from cell-to-cell interactions to the macroscopic tissue architecture.
  • Well-suited for simultaneous detection of multiple markers to identify specific cell subsets, document an immune response or quantify biomarkers of interest.
  • Automated and robust workflow from sample processing to multiplexed image acquisition and quantification.
  

Automated tissue slide imaging

Platform

Discovery XT (Ventana / Roche)

Staining type

  • Immunohistochemistry (IHC)
  • Immunohistofluorescence (IHF)

Sample format

  • Paraffin embedded tissues (FFPE sections)
  • Frozen tissues (Cryo-sections)
  • Tissue Micro Arrays (TMAs)
Multiplexed quantitative pathology imaging

Platform

Vectra Polaris (Perkin Elmer)

Sample format

Brightfield and fluorescence whole-slide scanning

Multispectral imaging

Up to 9 colors multiplexing

Readouts

Integrated tissue analysis software packages for  marker/biomarker quantification and spatial analysis

 

Illustrative data

Tumor infiltration in orthotopic glioma
Orthotopic glioma tumor-bearing model is characterized by tumor-infiltrating immune cells. Hematoxylin-associated IHC staining of brain sections of GL261 glioma-bearing mice (top left image) shows the presence of CD8+ cytotoxic lymphocytes infiltrating the tumor . Segmentation and quantification procedure of such CD8 staining is illustrated in the right images.

Orthotopic glioma tumor-bearing model is characterized by tumor-infiltrating immune cells. ...

IHC multispectral imaging
Illustration of multispectral imaging and color deconvolution process in brightfield imaging (IHC) that enables the identification and downstream quantification of multiple overlapping markers (CD8 in Red, CD163 in Blue, PDL1 in Purple and IDO1 in Brown) without the interference of autofluorescence as the signals are unmixed from one another.

Illustration of multispectral imaging and color deconvolution process in brightfield imaging ...

TLS analysis by multiparametric IHF
TLS analysis in cancer patient samples by multiparametric immunohistofluorescence. (A) Human TLS was highlighted through automated immunohistofluorescence approach (Ventana Discovery Ultra, Roche) multiplexing CD4, CD8, CD20, CD21, and CD23 markers. Following their acquisition (Vectra Polaris, Akoya Biosciences), multispectral images were processed for each marker deconvolution. (B) TLS characterization through CD8+ (cytotoxic T cells), CD4+ (helper T cells), CD21+ (follicular DC cells), CD20+/CD23- (immature B cells) and CD20+/CD23+ (mature B cells) cell populations.

TLS analysis in cancer patient samples by multiparametric immunohistofluorescence. (A) Human ...